4Indexed trials
drug · Product Intelligence
Donanemab
Pipeline Intelligence
Donanemab: 4 indexed trials, 2 sponsors; 0 linked Orange Book patents and 0 FDA-linked events where matched.
2Sponsors
0Orange Book patent links
0FDA-linked events
Development evidence
NCT03367403Eli Lilly and Company · alzheimersPHASE2
NCT05026866Eli Lilly and Company · alzheimersPHASE3
NCT06911944Michael Rafii, MD, PhD · alzheimersPHASE4
NCT07589595Eli Lilly and Company · alzheimersPHASE2
FDA / patent evidence
No FDA Orange Book product match is asserted for this intervention.
Regulatory context
FDA Orange Book coverage is U.S.-specific and is not a substitute for worldwide patent or regulatory review.